Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGM NASDAQ:IMVT NASDAQ:MOR NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$7.86+6.5%$8.48$6.21▼$17.17$764.15M1.2645,312 shs23,783 shsIMVTImmunovant$15.53-3.9%$16.29$12.72▼$32.10$2.71B0.451.49 million shs2.15 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AXENEXenon Pharmaceuticals$35.99-0.6%$34.92$26.74▼$46.00$2.78B1.17871,753 shs554,048 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group0.00%+1.79%-2.51%-47.66%+13.89%IMVTImmunovant0.00%-5.72%+6.18%+4.33%-45.53%MORMorphoSys0.00%0.00%0.00%0.00%0.00%XENEXenon Pharmaceuticals0.00%-7.65%-5.28%+13.09%-11.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$7.86+6.5%$8.48$6.21▼$17.17$764.15M1.2645,312 shs23,783 shsIMVTImmunovant$15.53-3.9%$16.29$12.72▼$32.10$2.71B0.451.49 million shs2.15 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AXENEXenon Pharmaceuticals$35.99-0.6%$34.92$26.74▼$46.00$2.78B1.17871,753 shs554,048 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group0.00%+1.79%-2.51%-47.66%+13.89%IMVTImmunovant0.00%-5.72%+6.18%+4.33%-45.53%MORMorphoSys0.00%0.00%0.00%0.00%0.00%XENEXenon Pharmaceuticals0.00%-7.65%-5.28%+13.09%-11.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMBGM Group 0.00N/AN/AN/AIMVTImmunovant 2.83Moderate Buy$33.60116.36% UpsideMORMorphoSys 0.00N/AN/AN/AXENEXenon Pharmaceuticals 3.00Buy$53.3048.10% UpsideCurrent Analyst Ratings BreakdownLatest BGM, IMVT, XENE, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.009/3/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$48.009/2/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.008/12/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $37.008/12/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $30.008/12/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.008/12/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $55.008/12/2025XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $43.008/11/2025IMVTImmunovantCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/28/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$17.00 ➝ $18.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold$18.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMBGM Group$25.10M30.44N/AN/A$7.34 per share1.07IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17XENEXenon Pharmaceuticals$9.43M294.29N/AN/A$9.90 per share3.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AIMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AXENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest BGM, IMVT, XENE, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/A8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGMBGM GroupN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMBGM GroupN/A1.821.45IMVTImmunovantN/A12.3212.32MORMorphoSys4.981.381.38XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMBGM GroupN/AIMVTImmunovant47.08%MORMorphoSys18.38%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipBGMBGM Group58.66%IMVTImmunovant1.80%MORMorphoSys0.05%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMBGM Group29897.22 million40.19 millionN/AIMVTImmunovant120174.32 million171.18 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableBGM, IMVT, XENE, and MOR HeadlinesRecent News About These CompaniesWhy Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?September 10, 2025 | zacks.comAlliancebernstein L.P. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Decreases Stake in Xenon Pharmaceuticals Inc. $XENESeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Purchases 78,390 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 7, 2025 | marketbeat.comWells Fargo & Company Reiterates Overweight Rating for Xenon Pharmaceuticals (NASDAQ:XENE)September 5, 2025 | marketbeat.comAlly Bridge Group NY LLC Trims Position in Xenon Pharmaceuticals Inc. $XENESeptember 5, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Acquired by Adage Capital Partners GP L.L.C.September 5, 2025 | marketbeat.comInvestors Buy High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)September 5, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Now Covered by Wells Fargo & CompanySeptember 5, 2025 | americanbankingnews.comXenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at Royal Bank Of CanadaSeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Has $4.28 Million Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comFirst Light Asset Management LLC Sells 532,676 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE is Vestal Point Capital LP's 9th Largest PositionSeptember 4, 2025 | marketbeat.comBirchview Capital LP Has $705,000 Stake in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Raises Stock Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 646,271 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comRoyal Bank Of Canada Reiterates Outperform Rating for Xenon Pharmaceuticals (NASDAQ:XENE)September 4, 2025 | americanbankingnews.comXenon Pharmaceuticals assumed with an Overweight at Wells FargoSeptember 3, 2025 | msn.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Braidwell LPSeptember 3, 2025 | marketbeat.comDriehaus Capital Management LLC Raises Stock Position in Xenon Pharmaceuticals Inc. $XENEAugust 31, 2025 | marketbeat.comSiren L.L.C. Sells 11,008 Shares of Xenon Pharmaceuticals Inc. $XENEAugust 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBGM, IMVT, XENE, and MOR Company DescriptionsBGM Group NASDAQ:BGM$7.86 +0.48 (+6.50%) Closing price 03:59 PM EasternExtended Trading$7.89 +0.03 (+0.38%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Immunovant NASDAQ:IMVT$15.53 -0.63 (-3.90%) Closing price 04:00 PM EasternExtended Trading$16.12 +0.59 (+3.80%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 09/12/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Xenon Pharmaceuticals NASDAQ:XENE$35.99 -0.22 (-0.61%) Closing price 04:00 PM EasternExtended Trading$36.02 +0.02 (+0.07%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
